Operator
Good morning, and welcome to the This autumn and monetary 2025 Monetary Outcomes Convention Name for HLS Therapeutics. (Operator Directions). This name is being recorded on Thursday, March 12, 2026. At the moment, I want to flip the decision over to David (sic) ( Dave ) Mason, Investor Relations, for the introductory remarks.
Dave Mason
Investor Relations Officer
Thanks, Joelle. Good morning, everybody, and thanks for becoming a member of us as we speak. With me on the decision is Craig Millian, Chief Govt Officer; John Hanna, Chief Monetary Officer; and Brian Walsh, Chief Industrial Officer.
Earlier this morning, we issued a information launch asserting our monetary outcomes for the three and 12 months ended December 31, 2025. This information launch, together with our MD&A and monetary statements is offered on our web site and on SEDAR+. Please word that slides accompanying as we speak’s name may be considered by way of the webcast, a hyperlink to which is offered in our earnings launch and on our web site on the Occasions web page.
Sure issues mentioned in as we speak’s convention name or solutions which may be given to questions might represent forward-looking statements. Precise outcomes might differ materially from these anticipated. Threat elements that would have an effect on outcomes are detailed within the firm’s annual data type, which has been filed on SEDAR+.
In the course of the name, we’ll check with adjusted EBITDA. Adjusted EBITDA doesn’t have any standardized which means prescribed by IFRS. Adjusted EBITDA is outlined in our press launch and annual filings that